Combination efficacy with checkpoint blockade therapy was further explored in the orthotopic 4T1 tumor model, where the addition of CB-1158 to the doublet regimen of anti-CTLA-4 and anti-PD-1 resulted in a significant reduction in growth of the primary tumor as well as a decrease in the number of lung metastases (Fig. 6b). This evidence concerns the gene CTLA4 and neoplasm.